AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 07/09/23

NEW YORK, NY / ACCESSWIRE / July 9, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE:AMRX). Investors who purchased Amneal securities are encouraged to obtain additional infor...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on Aug...

2023-07-05 13:23:58 ET Shares of Amneal Pharmaceuticals (NYSE: AMRX) were down more than 13% as of 12:45 p.m. ET on Wednesday after the pharmaceutical company announced both positive and negative news regarding its clinical pipeline. The stock is still up more than 30% this year...

2023-07-05 10:02:39 ET Gainers: Impel Pharmaceuticals ( IMPL ) +32% . Adicet Bio ( ACET ) +18% . C4 Therapeutics ( CCCC ) +17% . NLS Pharmaceutics ( NLSP ) +7% . Poseida Therapeutics ( PSTX ) +4% . Losers: Amneal Pharmaceu...

2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...

2023-07-03 14:34:31 ET The US FDA has issued a Complete Response Letter to Amneal Pharmaceuticals ( NYSE: AMRX ) for Parkinson's disease candidate IPX203. The stock is down ~5% in after-hours trading Monday. The agency said that an adequate scientific bridge was not es...

- Launches authorized generic for Xyrem ® (sodium oxybate) in the U.S., representing another new complex generic product launch - Receives U.S. FDA approval for five new complex generics in the second quarter - Remains on track to deliver more than 30 new generic launch...

- Letter requests additional pharmacokinetic data - No clinical efficacy or manufacturing issues identified Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from t...

Newly Released Report Details Company’s Progress and Contributions Toward Good Health and Well-Being as a Leading Provider of Affordable Medicines Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its ...

- Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma - Represents a high value, complex product launch for Amneal’s expanding injectable portfolio Amneal Pharmaceuticals, Inc. (N...